埃奇诺坎丁和凝血功能障碍事件
Hong Tham Pham1, Kim-Huong Truong-Nguyen2, Minh-Hoang Tran3
1Faculty of Pharmacy, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam.
Thrombosis journal
|February 18, 2026
概括
人们担心埃奇诺坎丁与药物相互作用以及凝血问题. 最近一项研究的方法限制可能会影响对黄素和凝血功能障碍事件的发现的可靠性.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床药房 临床药房
- 药品安全 药品安全
背景情况:
- 埃奇诺坎丁是一种抗真菌剂.
- 现实世界的证据表明,乙甘丁与凝血功能障碍之间存在联系.
- 人们对这些发现的方法和解释提出了担忧.
研究的目的:
- 批判性地评估研究的方法和解释,将 echinocandins 与凝血功能障碍事件联系起来.
- 确定可能影响报告结果的可靠性和影响的局限性.
主要方法:
- 审查研究设计,包括凝血事件的分类.
- 评估用于信号检测的统计方法.
- 对数据解释的评估,包括对时间性和信号可预测性的评估.
主要成果:
- 将高凝血和低凝血结合成"凝血功能障碍事件"可能会导致异质性.
- 对血小板缺血和血小板数量下降的潜在错误分类可能会影响结果.
- 使用了原始的信号估计,没有混调整和不适当的统计测试.
- 指出了对"发病时间"的误导性解释,以及对药监信号的不合理转化为可预测性.
结论:
- 关于研究设计,统计分析和数据解释的方法问题可能会限制从当前关于乙甘丁和凝血功能障碍的证据中得出的结论.
- 解决这些问题对于加强洞察力和指导未来对类诱导不良事件的研究至关重要.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.0K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.0K
Disorders of Hemostasis
2.3K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.3K
Coagulation
11.0K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
11.0K
Coagulation
1.5K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.5K
Extrinsic and Intrinsic Pathways of Hemostasis
13.5K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
13.5K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.5K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.5K


